- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03624972
Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
March 15, 2021 updated by: Fox Chase Cancer Center
Enhancing Patient-Provider Communication About Sexual Concerns in Breast Cancer: Patient Intervention Study
The goal of this study is to evaluate an educational video intervention (called Starting the Conversation) aimed to enhance breast cancer patients' beliefs about and communication with respect to sexual concerns.
In the current study, 128 breast cancer outpatients will be randomized to either participate in the video intervention and to receive a resource guide addressing sexual and menopausal health or to receive the resource guide alone.
Patients will be asked to participate in the video and/or read through the resource guide prior to their clinic visit with their breast cancer provider.
The investigators will examine effects of the interventions on patients' beliefs about communication about sexual health and on patients' communication about sexual health during clinic visits with their providers.
Secondarily, the investigators will examine effects of the interventions on sexual outcomes and other health outcomes, including psychological well-being and health-related QOL.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
153
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Receiving any treatment for breast cancer or have completed acute treatment for breast cancer < 10 years ago
- Attending clinic visits in the course of follow-up care (i.e., not an initial consult visit)
- Willing to have clinic visit audio recorded
Exclusion Criteria:
- Unable to speak English
- Eastern Cooperative Oncology Group (ECOG) Performance score > 2 OR too ill to participate as judged by physician, self-report, or observation of the research team member
- Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g., dementia, suicidal behavior, or psychosis), as observed or judged by the researcher or referring source.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Resources Only
Patients will receive a list of resources on sexual and menopausal health in breast cancer.
They will be asked to review the resources before their next clinic visit.
|
Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
|
Experimental: Resources + Video
Patients will receive a list of web resources on sexual and menopausal health in breast cancer.
In addition to the resources, patients will be asked to view an online video called "Starting the Conversation" and to complete an accompanying workbook.
Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit.
|
Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
|
No Intervention: Clinician Arm
Clinicians were consented in order to have their clinic visits audio recorded.
No outcomes data were collected from clinician participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Reported Self-Efficacy for Communicating About Sexual Health Issues
Time Frame: 2 weeks
|
Two items assessed patients' self-efficacy (confidence) for communicating with their breast cancer clinician about sexual health concerns in terms of either talking (item 1) or asking (item 2) about sexual health.
Response options used an 11-point scale (0=not at all confident/not at all to 10=extremely confident/very much).
Mean scores across the two items were used, ranging from 0-10.
Higher scores indicate higher self-efficacy.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About Sexual Health Issues
Time Frame: 2 months
|
Two items assessed patients' self-efficacy (confidence) for communicating with their breast cancer clinician about sexual health concerns in terms of either talking (item 1) or asking (item 2) about sexual health.
Response options used an 11-point scale (0=not at all confident/not at all to 10=extremely confident/very much).
Mean scores across the two items were used, ranging from 0-10.
Higher scores indicate higher self-efficacy.
|
2 months
|
Self-Reported Outcome Expectancies for Sexual Health Communication
Time Frame: 2 weeks
|
Five items assessed the belief that discussing sexual health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Sexual Health Communication
Time Frame: 2 months
|
Five items assessed the belief that discussing sexual health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Number of Patients Who Asked at Least One Question About Sexual Health at Their Clinic Visit
Time Frame: 2 weeks
|
As coded from clinic visit audio, the number of patients who ask at least one question about sexual health.
|
2 weeks
|
Number of Patients Who Initiate Conversation About Sexual Health in Their Clinic Visit
Time Frame: 2 weeks
|
As coded from clinic visit audio, the number of patients who raise the topic of sexual health during their encounter (out of encounters where a sexual health discussion occurred).
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment Rates (Feasibility)
Time Frame: baseline
|
Recruitment rates, as measured by percentage of patients enrolled (i.e., baselined) out of eligible patients approached for the study.
|
baseline
|
Retention Rates (Feasibility)
Time Frame: 2 weeks
|
Retention rates, as measured by percentage of patients who remain on study for 2-week follow-up assessment.
|
2 weeks
|
Retention Rates (Feasibility)
Time Frame: 2 months
|
Retention rates, as measured by percentage of patients who remain on study for 2-month follow-up assessment.
|
2 months
|
Intervention Acceptability
Time Frame: 2 weeks
|
Acceptability of intervention, as measured through the item "Overall, how satisfied were you with this program?".
Responses options include Very Satisfied, Satisfied, Dissatisfied, and Very Dissatisfied.
Responses of "satisfied" or "very satisfied" indicate acceptability.
Number of patients reporting acceptability and number of patients not reporting acceptability are presented.
|
2 weeks
|
Sexual Activity
Time Frame: 2 months
|
Sexual activity was measured by a single item asking (yes/no) whether the participant had any kind of sexual activity in the past 30 days.
|
2 months
|
Sexual Function
Time Frame: 2 months
|
Sexual function was assessed using the Lubrication, Vaginal Discomfort, Satisfaction, and Interest domain scores from the Patient-Reported Outcomes Measurement Information System Sexual Function and Satisfaction scale (PROMIS SexFS) Brief Profile Version 2.0.
Scores are converted to a T-score metric where a score of 50 equates to the mean of the U.S. population of sexually active adults (SD=10).
Higher scores for all domains except Vaginal Discomfort signify better function.
|
2 months
|
General Self-Efficacy for Communication With Provider
Time Frame: 2 months
|
Patients' self-efficacy for communicating with provider generally, as measured through the Perceived Efficacy in Patient-Physician Interactions Scale (PEPPI-5).
The PEPPI-5 is a five-item scale that measures patient confidence in communicating with providers.
Response options are on a scale from 1 (Not at All Confident) to 5 (Very Confident) and are summed for a total self-efficacy score (Range: 5-25).
Higher scores indicate higher self-efficacy.
|
2 months
|
Barriers to Communicating About Sexual Health
Time Frame: 2 months
|
Patient barriers to communication about sexual health, as measured through a 13-item scale.
Scale items cover potential reasons a patient might not want to discuss sexual health concerns with her provider (e.g., "I might become embarrassed").
Items are scored on a 1-5 scale where 1=Strongly Disagree and 5=Strongly Disagree.
A total barrier score will be taken from this scale (Range: 13-65).
Higher scores indicate more perceived barriers to communication.
|
2 months
|
Self-Reported Anxiety
Time Frame: 2 months
|
Patients self-reported anxiety, as measured through anxiety subscale of the Hospital Anxiety & Depression Scale (HADS).
The anxiety subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of anxiety.
|
2 months
|
Self-Reported Depression
Time Frame: 2 months
|
Patients self-reported depression, as measured through depression subscale of the Hospital Anxiety & Depression Scale (HADS).
The depression subscale consists of 7 items that are scored from 0 to 3. Summed scores range from 0 to 21, with higher scores indicating higher levels of depression.
|
2 months
|
Self-Reported Quality of Life
Time Frame: 2 months
|
Quality of life, as measured through the Abbreviated Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) total score.
The FACT-B contains 23 items about physical, functional, and emotional well-being in the context of breast cancer.
Scale items are scored from 0 to 4. Summed scores run from 0 to 92, with higher scores indicating higher quality of life.
|
2 months
|
Self-Reported Self-Efficacy for Communicating About About Treatment Side Effects
Time Frame: 2 weeks
|
Patients' self-reported self-efficacy for communication about treatment side effects with their breast cancer provider.
The items about treatment side effects consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about treatment side effects and asking her provider about treatment side effects.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About About Treatment Side Effects
Time Frame: 2 months
|
Patients' self-reported self-efficacy for communication about treatment side effects with their breast cancer provider.
The items about treatment side effects consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about treatment side effects and asking her provider about treatment side effects.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 months
|
Self-Reported Self-Efficacy for Communicating About About Menopausal Health
Time Frame: 2 weeks
|
Patients' self-reported self-efficacy for communication about menopausal health with their breast cancer provider.
The items about menopausal health consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about menopausal health and asking her provider about menopausal health.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 weeks
|
Self-Reported Self-Efficacy for Communicating About About Menopausal Health
Time Frame: 2 months
|
Patients' self-reported self-efficacy for communication about menopausal health with their breast cancer provider.
The items about menopausal health consist of 2 items within a larger 6-item scale which ask the patient how confident she is in talking to her provider about menopausal health and asking her provider about menopausal health.
Response options range from 0 (not at all confident) to 10 (extremely confident).
Mean scores will be reported.
|
2 months
|
Self-Reported Outcome Expectancies for Communication About Treatment Side Effects
Time Frame: 2 weeks
|
Five items assessed the belief that discussing treatment side effects with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Communication About Treatment Side Effects
Time Frame: 2 months
|
Five items assessed the belief that discussing treatment side effects with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Self-Reported Outcome Expectancies for Communication About Menopausal Health
Time Frame: 2 weeks
|
Five items assessed the belief that discussing menopausal health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 weeks
|
Self-Reported Outcome Expectancies for Communication About Menopausal Health
Time Frame: 2 months
|
Five items assessed the belief that discussing menopausal health with her breast cancer clinician would lead to positive outcomes (e.g., "find a solution to a problem").
Response options used an 11-point scale (0=not at all to 10=very much).
Mean scores across the five items were used, ranging from 0-10.
Higher scores indicate higher expectancies for positive outcomes.
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 27, 2018
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
July 20, 2018
First Submitted That Met QC Criteria
August 7, 2018
First Posted (Actual)
August 10, 2018
Study Record Updates
Last Update Posted (Actual)
March 16, 2021
Last Update Submitted That Met QC Criteria
March 15, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-833-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Pittsburgh; Case Western Reserve...RecruitingBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Stage III Breast CancerUnited States
Clinical Trials on Sexual and Menopausal Health Resources
-
Fox Chase Cancer CenterCompleted
-
Rigshospitalet, DenmarkActive, not recruitingQuality of Life | Sexual Dysfunction | Sexuality | Psychological | Symptoms and SignsDenmark
-
The University of Hong KongCompleted
-
Johns Hopkins Bloomberg School of Public HealthNative American Research Centers for HealthCompletedSexually Transmitted Diseases | Sexual Behavior | Chlamydia | Gonorrhea | Adolescent Behavior | Trichomonas | Unprotected Sex | Self EvaluationUnited States
-
University of GuadalajaraUniversidad de ColimaUnknown
-
Marmara UniversityNot yet recruitingNursing Education | Nursing Students | Nursing ModelTurkey
-
Gonabad University of Medical SciencesShahid Sadoughi University of Medical Sciences and Health ServicesCompleted
-
University of BaghdadCompletedSexual Behavior | Sexual Orientation Conflict Disorder | Sexual Arousal Disorder | Sexual Orientation | Sexual; Orientation, Relationship DisorderIraq
-
Child TrendsPower to Decide; Healthy Teen Network; MyHealthEd, IncRecruitingHealth Behavior | Sexually Transmitted Infections | Health Care Utilization | Unprotected SexUnited States
-
Necmettin Erbakan UniversityRecruitingMenopause | Sexual Behavior | SexualityTurkey